World’s First Early Alzheimer’s Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister’s Awardat the 12th Technology Management and Innovation Awards
TOKYO, Mar 25, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab) for the treatment of early Alzheimer’s disease (early AD *) has received the Prime Minister’s Award at the 12th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society (JATES **).The Technology Management and Innovation Awards was established in 2012 with the aim ofrecognizing outstanding examples of technology management that have produced world-changing innovations, and widely introduce them to society so that the awardees can serve as models for the next generation of managers and engineers. This year marks the 12th annual awards.This award recognized LEQEMBI as “a world-first treatment for early AD developed in Japan which selectively binds to and clears neurotoxic substances (abnormal proteins), thereby reducing the rate of disease progression. While companies and researchers around th…